Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and ...

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Nanjing Leads Biolabs Co., Ltd. ('Leads Biolabs' or the 'Company,' Stock Code: 9887.HK) announced on March 6, 2026 that the ...

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) support the ...

Gut microbiota may shape liver metastasis in small cell lung cancer and influence treatment response. Read more.

A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...

Baar, Switzerland Wednesday, March 4, 2026, 17:00 Hrs [IST] ...

Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer ...

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...

Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in ...